Streetbeat News

Regulatory

ATNF

180 Life Sciences Corp. (NASDAQ:ATNF) has filed a provisional patent for the combination of CBD and GLP-1 agonists for obesity and weight management. The company believes that the combination of these two compounds could stimulate a common therapeutic pathway. The company is currently in negotiations with third-party scientists for a research collaboration to test this theory. If successful, this could lead to human clinical trials.

Portfolio Pulse from Happy Mohamed

July 31, 2023 | 12:04 pm

SXTP

60 Degrees Pharmaceuticals has been awarded a Canadian patent for Tafenoquine, a drug used for the prevention of malaria in malaria-naive subjects.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 12:01 pm

BBIO

BridgeBio Pharma has announced a potential path for accelerated approval in the U.S. for BBP-418, a therapy for Limb-girdle Muscular Dystrophy Type 2I, based on FDA discussions. The company has also dosed the first patient with LGMD2I/R9 in its Phase 3 FORTIFY clinical trial of BBP-418 and is in the process of opening sites in Europe and Australia.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:36 am

FXI

China's cabinet has approved three new nuclear power station projects, according to Reuters citing state media. The government will also adjust and improve property policies. The news may impact the iShares China Large-Cap ETF (FXI).

Portfolio Pulse from Charles Gross

July 31, 2023 | 11:14 am

MRNS

The European Commission has approved Marinus Pharmaceuticals' Ztalmy (Ganaxolone) oral suspension for the adjunctive treatment of epileptic seizures associated with Cyclin-dependent kinase-like 5 deficiency disorder in patients aged two to 17 years.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:14 am

RDHL

Redhill Biopharma's RHB-107 (Upamostat) has been accepted for inclusion in a multinational platform trial for early Covid-19 outpatient treatment. The trial, supported by the U.S. Government, will be conducted in the U.S., Thailand, Ivory Coast, and South Africa. The Phase 2 study, predominantly funded by the U.S. Government Department of Defense, has received FDA clearance to start and is estimated to be completed by the end of 2024.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 11:08 am

MSFT

The Kremlin is reportedly using popular video games like Minecraft, owned by Microsoft Corporation (NASDAQ:MSFT), and World of Tanks to advance its propaganda among younger audiences. Russian players in Minecraft have recreated battles and captured cities, sharing videos on VKontakte, a popular social media network in Russia. Microsoft's president, Brad Smith, acknowledged these efforts but downplayed their significance. Clint Watts, head of Microsoft's threat analysis team, noted that Russian paramilitary force, the Wagner Group, used platforms like Discord and Steam to promote narratives supporting the Kremlin's views.

Portfolio Pulse from Ananya Gairola

July 31, 2023 | 11:01 am

AAPL

ETHUSD

MATICUSD

US Representatives Gus Bilirakis and Jan Schakowsky have expressed concerns about Apple's App Store Guidelines and their potential impact on non-fungible tokens (NFTs) and blockchain technologies. They believe that Apple's limitations may restrict the development and integration of these technologies. They also questioned whether Apple has plans to develop apps utilizing blockchain or related technologies.

Portfolio Pulse from Mehab Qureshi

July 31, 2023 | 10:53 am

AVAV

FXI

SPY

UAVS

VISL

China's Commerce Ministry has announced export controls on drone-related equipment, effective from September 1. This move comes amid ongoing tech tensions between China and the US.

Portfolio Pulse from Charles Gross

July 31, 2023 | 10:14 am

CTXR

Citius Pharmaceuticals received a Complete Response Letter from the FDA for Lymphir (Denileukin Diftitox) for relapsed/refractory cutaneous T-cell lymphoma, causing its shares to trade lower.

Portfolio Pulse from Benzinga Newsdesk

July 31, 2023 | 9:39 am